Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Non-Small Cell Lung Cancer - Pipeline Review, H2 2013 market report to its offering
Non-Small Cell Lung Cancer - Pipeline Review, H2 2013

Summary

, 'Non-Small Cell Lung Cancer - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. Non-Small Cell Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
- A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Shionogi & Co., Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
Nektar Therapeutics
Inovio Biomedical Corporation
MedImmune LLC
Isis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
YM BioSciences Inc.
Celltrion, Inc.
Prolexys Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Biocon Limited
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
ImmunoGen, Inc.
Laboratoires Pierre Fabre SA
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
SuperGen, Inc.
Taiho Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Exelixis, Inc.
Aduro BioTech
Cyclacel Pharmaceuticals Inc.
Alfacell Corporation
Celgene Corporation
Bayer AG
Geron Corporation
Aeolus Pharmaceuticals, Inc.
Merck KGaA
EntreMed, Inc.
Hana Biosciences, Inc.
Celldex Therapeutics, Inc.
AEterna Zentaris Inc.
ImmunoCellular Therapeutics, Ltd.
Idera Pharmaceuticals, Inc.
Ariad Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Benitec Ltd.
MethylGene Inc
Northwest Biotherapeutics, Inc.
Novogen Limited
Cleveland BioLabs, Inc.
Oncothyreon Inc
Compugen Ltd.
OXiGENE, Inc.
Peregrine Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
Curis, Inc.
Telik, Inc.
CytRx Corporation
Regeneron Pharmaceuticals, Inc.
Oncogenex Pharmaceuticals, Inc.
MOLOGEN AG
Quest PharmaTech Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Natco Pharma Limited
Simcere Pharmaceutical Group
Sun Pharma Advanced Research Company
Morphotek, Inc.
Spectrum Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
CIMAB S.A.
Bionucleon Srl
GANYMED Pharmaceuticals AG
Ora Bio Ltd.
Philogen S.p.A.
NovaRx Corporation
Nerviano Medical Sciences S.r.l.
Cadila Pharmaceuticals Ltd.
Hutchison MediPharma Limited
immatics biotechnologies GmbH
Vaxon Biotech
CureVac GmbH
BioNumerik Pharmaceuticals, Inc.
Altor BioScience Corporation
Alder Biopharmaceuticals Inc.
Ascenta Therapeutics, Inc.
Cerulean Pharma, Inc.
Heat Biologics, Inc.
MacroGenics, Inc.
OncoMed Pharmaceuticals, Inc.
DanDrit Biotech A/S
Azaya Therapeutics, Inc.
CanBas Co., Ltd.
Merrimack Pharmaceuticals, Inc.
Neotropix, Inc.
Mersana Therapeutics, Inc.
Axelar AB
Proacta, Inc.
Advenchen Laboratories, LLC
MolMed S.p.A.
Innogene Kalbiotech Pte Ltd.
Syndax Pharmaceuticals, Inc.
KangLaiTe USA
Mirna Therapeutics, Inc.
Globeimmune, Inc.
Tragara Pharmaceuticals, Inc.
Taiwan Liposome Company
Cellceutix Corporation
PharmaMar, S.A.
CG Therapeutics, Inc.
Quintessence Biosciences, Inc.
Sirnaomics, Inc.
Biothera
Nereus Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Medisyn Technologies, Inc.
Pique Therapeutics
Clovis Oncology, Inc.
Toko Pharmaceutical Industries Co., Ltd.
Cancer Therapeutics CRC Pty Ltd
Medical Enzymes AG
KAEL-GemVax
iCeutica, Inc.
Mebiopharm Co., Ltd.
Vichem Chemie Research Ltd.
Agennix AG
Regulon Inc.
CellAct Pharma GmbH
Oncozyme Pharma Inc.
Optimum Therapeutics, LLC

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/140869/non-small-cell-lung-cancer-pipeline-review-h2-2013.html